Insights
Insights & Perspectives
Thought leadership from the intersection of sterilization science, regulatory evolution, and validated process engineering.
ISO 22441 Beyond the U.S.: How VHP Sterilization Now Navigates EU MDR, Health Canada, TGA, and PMDA
ISO 22441:2022 is on the FDA consensus list. Notified Bodies in Europe are formally certifying VHP processes against it. Health Canada, TGA, and PMDA accept the framework. For any company with a global device portfolio, VHP validation done once to ISO 22441 now travels farther than it ever has.
Sterilization for CHIPS Act Fabs: What 18 New Semiconductor Facilities Mean for Contamination Control
Eighteen new semiconductor fabrication facilities broke ground in the United States in 2025 under CHIPS Act funding. Every one of them requires a validated cleanroom decontamination program. The contamination control problem inside a modern fab is structurally identical to pharmaceutical cleanrooms — and the solution set is the same.
Manufacturing Environment Decontamination for Cell and Gene Therapies: What FDA's 2026 CMC Flexibility Means for VHP
FDA's January 2026 CMC flexibility guidance accelerates cell and gene therapy commercialization. MHRA's decentralized manufacturing framework expands the production footprint. Both developments concentrate advanced therapy manufacturing in environments where contamination is an existential process risk — and where VHP is the only Category A-recognized low-temperature decontamination option.
Design It In: Why Your R&D Phase Is the Best Time to Choose VHP Sterilization
The sterilization method you choose during R&D determines your material options, packaging design, regulatory pathway, and supply chain architecture. Choosing VHP early eliminates the constraints that choosing late creates.
Why Irradiation Sterilizes the Biology Out of Your Allograft
Gamma irradiation achieves sterility at the cost of what makes allograft tissue work. Published evidence on collagen degradation, growth factor denaturation, and loss of osteoinductive potential — and what the alternative looks like.
Why Leading Sterilization Facilities Are Adding VHP to Their EtO Operations
EtO sterilization facilities operating as single-technology operations are leaving a growing category of products — and the revenue they represent — on the table. The case for adding VHP.
How to Add VHP Capability: A Practical Guide for Existing Sterilization Facilities
Adding VHP sterilization to an existing EtO facility is not a rip-and-replace project. It is a sequential, well-defined process with known infrastructure requirements, a structured validation pathway, and a realistic timeline for a facility that already speaks the language of regulated sterilization.
The Products Your EtO Facility Can't Sterilize — And How VHP Opens the Door
3D-printed porous implants, bioabsorbable polymers, cell therapy components, and combination products represent the fastest-growing segments of the medical device market — and each has a specific reason EtO is the wrong tool for the job.
FDA Reclassifies VHP to Category A: What It Means for Medical Device Manufacturers
The FDA's reclassification of vaporized hydrogen peroxide sterilization to Category A formally recognizes VHP as an established sterilization method — a validation of the science PuroGen has practiced for three decades.
The EtO Transition: Timeline, Implications, and Alternatives
EPA mandates for 90% ethylene oxide emission reductions are reshaping the sterilization landscape. Understanding the timeline and evaluating validated alternatives is no longer optional for device manufacturers.
Non-Irradiated Tissue Sterilization: 30 Years of Preserving Biological Integrity
From the first supercritical CO₂ processes to today's SteriFlex platform, PuroGen's approach to tissue sterilization has always prioritized what matters most: preserving the biology that makes the graft work.
Why Programmable Sterilization Matters for Next-Generation Biologics
As biologics grow more complex, sterilization must become more precise. Programmable parametric control isn't a feature — it's a necessity for the next generation of cell therapies, gene therapies, and engineered tissues.
Complete Custody and Control: Why Tissue Banks Are Bringing Sterilization In-House
Every tissue bank that ships allografts to a third-party irradiator surrenders custody of its most valuable asset. The operational, quality, and regulatory case for in-house VHP sterilization.
The Clinical Case for Non-Irradiated Allografts: Osteoinductivity, Osteoconductivity, and Mechanical Integrity
Surgeons are asking what happened to the graft before it reached the OR. Non-irradiated allografts preserve the osteoinductive, osteoconductive, and biomechanical properties that determine clinical outcomes.
Why Small Manufacturers Are Bringing Sterilization In-House — And Why the Economics Now Work
The assumption that in-house sterilization only makes sense at scale was built on the economics of EtO and irradiation infrastructure. VHP changes the math — especially for manufacturers of high-value, low-volume, and temperature-sensitive products.
From Bench to Validated Process: The VHP Sterilization Pathway for Device Manufacturers
ISO 22441 defines the validation framework. FDA Category A defines the regulatory pathway. For device manufacturers with IQ/OQ/PQ experience, the VHP validation lifecycle is structurally familiar — and faster than most expect.
What 'Occluded Surfaces' Actually Mean for Your VHP Validation — and Why Parametric Control Is the Answer
FDA warning letters to Catalent (November 2025) and Simtra (March 2026) both identified occluded surfaces as VHP decontamination failure modes. This is a first-principles physics problem. The cure is not geometry avoidance — it is parametric precision.
VHP in Pharmaceutical Isolators: What Annex 1, FDA Warning Letters, and 21 CFR 211.113(b) Are Actually Requiring
Two FDA warning letters — Catalent Indiana (November 2025) and Simtra BioPharma (March 2026) — both cite VHP decontamination failures in pharmaceutical isolators and RABS. The findings reveal what FDA inspectors are now specifically scrutinizing, and what site-specific VHP validation must actually demonstrate.
The EPA's Proposed EtO Reconsideration: What March 2026 Actually Means for Device Manufacturers
On March 17, 2026, the EPA proposed rescinding the 2024 Biden-era EtO emission standards — the most significant regulatory reversal in commercial sterilization in two decades. The reconsideration is not a resolution. For manufacturers who depend on EtO, it is a temporary deceleration of pressure, not an elimination of it.
Sterilizing Seed Banks: Why Genetic Integrity Preservation Is the Hardest Constraint in Agricultural Biotechnology
A sterile seed that will not germinate is worthless. In every other sterilization context the objective is a single variable — kill the microorganisms. In seed banks and agricultural biotech laboratories the objective is two simultaneous variables: kill the microorganisms and preserve the biology. VHP is the only validated sterilization modality that satisfies both constraints at the same time.
From Spore to Standard: How ISO 22441 Validation Compares to ISO 11135 (EtO) and ISO 11137 (Radiation)
The most common objection to VHP adoption among experienced validation teams is unfamiliarity with ISO 22441. For teams fluent in ISO 11135 for EtO or ISO 11137 for radiation, the structural parallels are exact. The biological indicator organism is the same. The SAL target is the same. The IQ/OQ/PQ lifecycle is the same. What differs is the method-specific parameters — and those differences are precisely defined.
The VHP Market Is Heading to $3.4 Billion. Here Is What That Means for Manufacturers Who Haven't Yet Decided.
The vaporized hydrogen peroxide sterilization market is forecast to grow from $1.45 billion in 2025 to $3.4 billion by 2035 at an 8.9% compound annual growth rate. That figure is not a marketing claim — it is the structural consequence of regulatory, operational, and supply chain forces that are already in motion. What it means for manufacturers still on the sidelines is a different question than what the headline number suggests.
Cobalt-60 Shortages, Tariff Pressure, and EtO Uncertainty: The Case for Sterilization Sovereignty
Approximately 50% of medical devices are sterilized by ethylene oxide. Another 40% by gamma irradiation, which depends on a cobalt-60 supply chain with a small number of global producers and no near-term capacity expansion. Add tariff pressure on imported sterilization services and imported sterilization equipment, and the case for treating sterilization as a strategic supply chain variable — rather than an outsourced commodity — has never been more concrete.
Two Years After Category A: The VHP Adoption Landscape in 2026
The FDA's January 2024 Category A reclassification opened a defined pathway for VHP sterilization adoption. Two years later, the landscape has shifted — ISO 22441 has matured, EPA EtO deadlines are compressing, and the first wave of in-house VHP deployments is underway.
Have a topic you'd like us to address? Let us know.
Get in touch